Laboratory Evaluation of the Liat HIV Quant (IQuum) Whole-Blood and Plasma HIV-1 Viral Load Assays for Point-of-Care Testing in South Africa
Open Access
- 1 May 2015
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (5), 1616-1621
- https://doi.org/10.1128/jcm.03325-14
Abstract
Point-of-care (POC) HIV viral load (VL) testing offers the potential to reduce turnaround times for antiretroviral therapy monitoring, offer near-patient acute HIV diagnosis in adults, extend existing centralized VL services, screen women in labor, and prompt pediatrics to early treatment. The Liat HIV Quant plasma and whole-blood assays, prerelease version, were evaluated in South Africa. The precision, accuracy, linearity, and agreement of the Liat HIV Quant whole-blood and plasma assays were compared to those of reference technologies (Roche CAP CTMv2.0 and Abbott RealTime HIV-1) on an HIV verification plasma panel ( n = 42) and HIV clinical specimens ( n = 163). HIV Quant plasma assay showed good performance, with a 2.7% similarity coefficient of variation (CV) compared to the Abbott assay and a 1.8% similarity CV compared to the Roche test on the verification panel, and 100% specificity. HIV Quant plasma had substantial agreement ( p c [concordance correlation] = 0.96) with Roche on clinical specimens and increased variability ( p c = 0.73) in the range of R 2 = 0.99). Clinical sensitivity at a viral load of 1,000 copies/ml of the HIV Quant plasma and whole-blood assays compared to that of the Roche assay ( n = 94) was 100% (confidence interval [CI], 95.3% to 100%). The specificity of HIV Quant plasma was 88.2% (CI, 63.6% to 98.5%), and that for whole blood was 41.2% (CI, 18.4% to 67.1%). No virological failure (downward misclassification) was missed. Liat HIV Quant plasma assay can be interchanged with existing VL technology in South Africa. Liat HIV Quant whole-blood assay would be advantageous for POC early infant diagnosis at birth and adult adherence monitoring and needs to be evaluated further in this clinical context. LIAT cartridges currently require cold storage, but the technology is user-friendly and robust. Clinical cost and implementation modeling is required.Keywords
This publication has 20 references indexed in Scilit:
- Use of a Prequalification Panel for Rapid Scale-Up of High-Throughput HIV Viral Load TestingJournal of Clinical Microbiology, 2012
- Opportunities and Challenges for Cost-Efficient Implementation of New Point-of-Care Diagnostics for HIV and TuberculosisThe Journal of Infectious Diseases, 2012
- Use of the community viral load as a population-based biomarker of HIV burdenAIDS, 2012
- Quantifying HIV for Monitoring Antiretroviral Therapy in Resource‐Poor SettingsThe Journal of Infectious Diseases, 2010
- A Rapid and Automated Sample‐to‐Result HIV Load Test for Near‐Patient ApplicationThe Journal of Infectious Diseases, 2010
- Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settingsJournal of Antimicrobial Chemotherapy, 2009
- HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 CJournal of Antimicrobial Chemotherapy, 2008
- Multisite Comparison of Reproducibility and Recovery from the Standard and Ultrasensitive Roche AMPLICOR HIV-1 MONITOR AssaysJournal of Clinical Microbiology, 2001
- HIV-1 RNA Detection in Plasma for the Diagnosis of Infection in NeonatesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986